These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29406263)

  • 1. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities.
    Agrahari V; Agrahari V
    Drug Discov Today; 2018 May; 23(5):974-991. PubMed ID: 29406263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of nanomedicines: A reflection on a field under construction needed for clinical translation success.
    Coty JB; Vauthier C
    J Control Release; 2018 Apr; 275():254-268. PubMed ID: 29454063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges associated and approaches for successful translation of nanomedicines into commercial products.
    Agrahari V; Hiremath P
    Nanomedicine (Lond); 2017 Apr; 12(8):819-823. PubMed ID: 28338401
    [No Abstract]   [Full Text] [Related]  

  • 4. Current hurdles to the translation of nanomedicines from bench to the clinic.
    Đorđević S; Gonzalez MM; Conejos-Sánchez I; Carreira B; Pozzi S; Acúrcio RC; Satchi-Fainaro R; Florindo HF; Vicent MJ
    Drug Deliv Transl Res; 2022 Mar; 12(3):500-525. PubMed ID: 34302274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.
    Operti MC; Bernhardt A; Grimm S; Engel A; Figdor CG; Tagit O
    Int J Pharm; 2021 Aug; 605():120807. PubMed ID: 34144133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Regulatory Considerations for Nanomedicines.
    Subin TS; Vijayan V; Kumar KJR
    Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
    Ehmann F; Sakai-Kato K; Duncan R; Hernán Pérez de la Ossa D; Pita R; Vidal JM; Kohli A; Tothfalusi L; Sanh A; Tinton S; Robert JL; Silva Lima B; Amati MP
    Nanomedicine (Lond); 2013 May; 8(5):849-56. PubMed ID: 23656268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nanomedicines alliance: an industry perspective on nanomedicines.
    Malinoski FJ
    Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines: addressing the scientific and regulatory gap.
    Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
    Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Elucidative Review to Analytically Sieve the Viability of Nanomedicine Market.
    Kad A; Pundir A; Arya SK; Bhardwaj N; Khatri M
    J Pharm Innov; 2022; 17(1):249-265. PubMed ID: 32983280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.
    Hare JI; Lammers T; Ashford MB; Puri S; Storm G; Barry ST
    Adv Drug Deliv Rev; 2017 Jan; 108():25-38. PubMed ID: 27137110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane-encapsulated camouflaged nanomedicines in drug delivery.
    Ghosh S; Girigoswami K; Girigoswami A
    Nanomedicine (Lond); 2019 Aug; 14(15):2067-2082. PubMed ID: 31355709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microfluidic Manufacture of Lipid-Based Nanomedicines.
    Osouli-Bostanabad K; Puliga S; Serrano DR; Bucchi A; Halbert G; Lalatsa A
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicines: From Bench to Bedside and Beyond.
    Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
    AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges.
    Haque S; Whittaker MR; McIntosh MP; Pouton CW; Kaminskas LM
    Nanomedicine; 2016 Aug; 12(6):1703-24. PubMed ID: 27033834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.
    Nijhara R; Balakrishnan K
    Nanomedicine; 2006 Jun; 2(2):127-36. PubMed ID: 17292125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.